CJC-1295 and Ipamorelin in Research: Dosing Parameters and Study Designs

Overview

CJC-1295 and Ipamorelin are two distinct growth hormone secretagogues that have been studied both individually and in combination in preclinical and clinical research. CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH), while Ipamorelin is a selective growth hormone secretagogue receptor (GHSR) agonist. This article reviews the dosing parameters and study designs reported in published research. All content is for research reference only.

CJC-1295: Mechanism and Research Doses

CJC-1295 (also known as DAC:GRF when conjugated to a Drug Affinity Complex) is a modified GHRH analogue with an extended half-life due to its binding to serum albumin. Unlike native GHRH (half-life ~7 minutes), CJC-1295 with DAC has a reported half-life of 6–8 days in humans, enabling less frequent dosing in research protocols.

Key published study — Alba et al. (2006): A clinical study published in The Journal of Clinical Endocrinology & Metabolism administered CJC-1295 to healthy adults at doses of 30, 60, 120, or 180 µg/kg subcutaneously. The study found dose-dependent increases in GH and IGF-1 levels, with IGF-1 remaining elevated above baseline for 28 days after a single injection at higher doses. No serious adverse events were reported [1].

Animal research — GHRHKO mouse model: Alba et al. also demonstrated that once-daily CJC-1295 administration maintained normal body composition and growth in growth hormone-releasing hormone knockout (GHRHKO) mice, establishing its utility as a research tool in GH deficiency models [2].

Doses used in published animal studies typically range from 1–30 µg/kg subcutaneously or intraperitoneally, with frequency varying from daily to once weekly depending on whether the DAC-conjugated or non-DAC form is used.

Ipamorelin: Mechanism and Research Doses

Ipamorelin is a pentapeptide GHSR agonist that selectively stimulates GH release without significantly affecting cortisol, prolactin, or ACTH — a selectivity profile that distinguishes it from earlier GHRPs like GHRP-6. This selectivity makes it a useful research tool for studying GH secretion in isolation.

Key published study — Raun et al. (1998): The original characterization of Ipamorelin published in European Journal of Endocrinology used doses of 1–100 µg/kg in rats and pigs, demonstrating selective GH release with a favorable safety profile compared to GHRP-6 and GHRP-2 [3].

Bone density research: Svensson et al. (2000) administered Ipamorelin at 200 µg/kg/day subcutaneously to female rats for 12 weeks and observed significant increases in bone mineral density compared to controls, without effects on cortisol [4].

Doses used in published animal studies typically range from 10–300 µg/kg depending on the endpoint being studied.

CJC-1295 + Ipamorelin Combination

The combination of a GHRH analogue (CJC-1295) with a GHSR agonist (Ipamorelin) is based on the principle of synergistic GH release — GHRH increases the number of somatotrophs releasing GH, while GHSR agonists amplify the pulse amplitude. This combination has been used in research protocols studying GH secretion dynamics.

No published peer-reviewed studies have specifically examined the CJC-1295 + Ipamorelin combination in controlled trials. The combination rationale is extrapolated from the known mechanisms of each compound individually.

Reconstitution

Both CJC-1295 and Ipamorelin are supplied as lyophilized powders and are reconstituted in bacteriostatic water following standard peptide reconstitution protocols. See our [Peptide Reconstitution Guide](/research/peptide-reconstitution-bac-water-guide) for detailed instructions.

Important Note

All dosing information refers to parameters used in published preclinical and clinical research. CJC-1295 and Ipamorelin are sold by Pure Pharm Peptides for research use only and are not intended for human or animal consumption.

For research use only. Not for human or animal consumption.

References

1. Alba, M., et al. (2006). Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American Journal of Physiology — Endocrinology and Metabolism, 291(6), E1290–E1294.
2. Alba, M., et al. (2006). Dose-response relationships of CJC-1295 in healthy adults. Journal of Clinical Endocrinology & Metabolism, 91(3), 799–805.
3. Raun, K., et al. (1998). Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 139(5), 552–561.
4. Svensson, J., et al. (2000). Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure. Journal of Clinical Endocrinology & Metabolism, 85(11), 4065–4072.